Advertisement
U.S. markets open in 4 hours 40 minutes

Pyxis Oncology, Inc. (PYXS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.47-0.12 (-1.82%)
At close: 04:00PM EST
6.11 -0.36 (-5.56%)
Pre-Market: 04:00AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close6.59
Open6.60
Bid0.00 x 1100
Ask0.00 x 800
Day's Range5.90 - 6.66
52 Week Range1.35 - 6.92
Volume806,730
Avg. Volume669,394
Market Cap292.089M
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-2.51
Earnings DateMar 22, 2024 - Mar 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PYXS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pyxis Oncology, Inc.
    Daily – Vickers Top Buyers & Sellers for 09/29/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • GlobeNewswire

    Pyxis Oncology Announces $50 Million Private Placement

    BOSTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that it has agreed to sell 8,849,371 shares of its common stock at a price of $4.78 per share and pre-funded warrants to purchase 1,611,215 shares of its common stock at a price per pre-funded warrant of $4.779 to a select group of institutional and accredited healthcare specialist

  • GlobeNewswire

    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors approved a stock option grant to Ken Kobayashi, M.D., the Company’s newly appointed Chief Medical Officer, in connection with his employment with the Company effective on November 27, 2023. The equity award was granted un

  • GlobeNewswire

    Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

    Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalitiesBOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer (CMO), effective November 27, 2023. Dr. Kobayashi brings extensive